Phase I PIANO Trial—pipac-Oxaliplatin and Systemic Nivolumab Combination for Gastric Cancer Peritoneal Metastases: Clinical and Translational Outcomes

R. Sundar, D. K. A. Chia, J. J. Zhao, A. R. Y. B. Lee, G. Kim, H. L. Tan, A. Pang, A. Shabbir,W. Willaert, H. Ma,K. K. Huang, T. Hagihara, A. L. K. Tan, C. -A. J. Ong, J. S. M. Wong,C. J. Seo, R. Walsh, G. Chan,S. W. Cheo, C. C. C. Soh, E. Callebout,K. Geboes, M. C. H. Ng, J. H. Y. Lum, W. Q. Leow, S. Selvarajan,A. Hoorens, W. H. Ang, H. Pang, P. Tan,W. P. Yong, C. S. L. Chia,W. Ceelen,J. B. Y. So

ESMO OPEN（2024）

Cited 0|Views3

Key words

immunotherapy,locoregional therapy,PIPAC,tumor microenvironment,gastric cancer,intraperitoneal,peritoneal metastases,peritoneum,niche

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined